Stomach cancer hope: triple therapy may boost tumor clearance before surgery
NCT ID NCT07408609
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether adding low-dose radiotherapy and the immunotherapy drug tislelizumab to standard chemotherapy can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 114 participants will be randomly assigned to receive either the combination therapy or chemotherapy alone before surgery. The main goal is to see if the combination leads to a higher rate of complete tumor disappearance (pathological complete response) at the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tislelizumab (an immunotherapy drug), oxaliplatin, capecitabine, and low-dose radiation
- What this could lead to
- If successful, this combination could improve the chance of eliminating all visible cancer before surgery, potentially leading to better long-term outcomes for patients with locally advanced gastric cancer.
- What could go wrong
- This is a small, early-phase (phase II) trial, so results may not be definitive. Adding immunotherapy and radiation to chemotherapy may increase side effects, and the approach might not work better than chemotherapy alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common heart drug boost cancer treatment? a trial puts propranolol to the test
- Triple-Drug cocktail aims to wipe out stomach tumors before surgery
- New drug combo aims to outperform immunotherapy in Hard-to-Treat stomach cancer
- Triple threat before surgery: could a new combo wipe out stomach cancer cells?
- New drug cocktail aims to shrink stomach tumors before surgery
- Arterial chemo combo shows promise in stomach cancer trial